Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29304921.
- Also identified by DOI 10.1016/j.mayocp.2017.09.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program to reduce day-100 all-cause mortality. Currently our mortality has been reduced to 0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater. Outpatient transplantation is safe and reduces patient-incurred costs.
Medical subject headings
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Patient Safety
- Transplantation, Autologous